Selinexor - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for selinexor and what is the scope of freedom to operate?
Selinexor
is the generic ingredient in one branded drug marketed by Karyopharm Theraps and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Selinexor has one hundred and thirty-three patent family members in thirty-nine countries.
One supplier is listed for this compound.
Summary for selinexor
International Patents: | 133 |
US Patents: | 10 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 138 |
Patent Applications: | 405 |
What excipients (inactive ingredients) are in selinexor? | selinexor excipients list |
DailyMed Link: | selinexor at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for selinexor
Generic Entry Date for selinexor*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for selinexor
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
AbbVie | Phase 3 |
Ruijin Hospital | Phase 2 |
Bristol-Myers Squibb | Phase 1/Phase 2 |
Pharmacology for selinexor
Drug Class | Nuclear Export Inhibitor |
Mechanism of Action | Nuclear Export Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for selinexor
US Patents and Regulatory Information for selinexor
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-004 | Apr 15, 2021 | RX | Yes | Yes | 11,807,629 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-005 | Mar 10, 2025 | RX | Yes | No | 9,714,226 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 10,544,108 | ⤷ Try for Free | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 9,714,226 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-005 | Mar 10, 2025 | RX | Yes | No | 9,079,865 | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for selinexor
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Stemline Therapeutics B.V. | Nexpovio | selinexor | EMEA/H/C/005127 NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. |
Authorised | no | no | no | 2021-03-26 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for selinexor
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 201700880 | POLYMORPHS OF SELINEXOR | ⤷ Try for Free |
South Korea | 102022715 | ⤷ Try for Free | |
Spain | 2926377 | ⤷ Try for Free | |
Cyprus | 1119783 | ⤷ Try for Free | |
Montenegro | 02936 | MODULATORI TRANSPORTA U- I IZ-JEZGRA, KOJI SADRŽE HIDRAZID, I NJIHOVE UPOTREBE (HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF) | ⤷ Try for Free |
Japan | 2023052622 | セリネクソールの多形体 | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for selinexor
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2736887 | LUC00219 | Luxembourg | ⤷ Try for Free | PRODUCT NAME: SELINEXOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1537 20210329 |
2736887 | 132021000000143 | Italy | ⤷ Try for Free | PRODUCT NAME: SELIXENOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(NEXPOVIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1537, 20210329 |
2736887 | CA 2021 00031 | Denmark | ⤷ Try for Free | PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329 |
2736887 | CR 2021 00031 | Denmark | ⤷ Try for Free | PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329 |
2736887 | PA2021007 | Lithuania | ⤷ Try for Free | PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326 |
2736887 | 2190030-3 | Sweden | ⤷ Try for Free | PRODUCT NAME: SELINEXOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1537 20210329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Selinexor
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.